President Donald Trump has unveiled his TrumpRx website, offering over 40 drugs at steeply discounted prices to cash-paying patients.
The direct-to-consumer (DTC) channel was launched on Thursday (5 February) and features drugs made by the first five drug manufacturers that signed pricing deals with the Trump Administration under the Most Favored Nation (MFN) policy. This includes AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
“Americans have long been paying the highest drug prices anywhere in the world. While other countries often paid pennies on the dollar for the exact same drugs. We were essentially subsidising the entire world and subsidising by hundreds of billions of dollars every year,” Trump claimed at an event at the White House on 5 February.
“Starting tonight, dozens of the most commonly used prescription drugs will be available at dramatic discounts for all consumers through a new website called TrumpRx.gov,” Trump added.
In 2023, 92% of US patients had health insurance for either some or the whole year. However, research suggests that around 60% of individuals paid out-of-pocket cash for prescription drugs in 2022.
The inclusion of Eli Lilly and Novo Nordisk’s weight loss drugs are perhaps the most significant. Together, their glucagon-like peptide-1 receptor agonists (GLP-1RAs) for obesity, Zepbound and Wegovy, generated over $21bn in the US in 2025 alone.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataOn TrumpRx, injectable Wegovy will fall from $1,349 to an average price of $350. The monthly price of Novo’s new Wegovy pill will fall from $1,349 to $149, depending on dosage strength. While the website compares the markdowns to US list prices, Novo offers the drugs on its own DTC at much cheaper costs – oral Wegovy, for example, is sold for the same price as TrumpRx, $149 per month. Online telehealth provider Hims & Hers also announced it would sell a compounded version of the pill for a starting price of $49, further complicating the pricing landscape in the US.
The monthly price of Zepbound will reduce from $1,088 to an average price of $346 and as low as $299, depending on dosage strength. As with Novo, Lilly also sells its weight loss drugs at steeply discounted prices on its DTC platform LillyDirect. Indeed, users ordering a vial of Zepbound on TrumpRx are redirected to the LillyDirect website. Patients seeking a Wegovy pen are instead given a pharmacy coupon.
Pfizer is so far the largest participant on TrumpRx, with over 30 medications included.
Pfizer CEO Albert Bourla said: “As the first pharmaceutical company to support President Trump in addressing this imbalance, we’re proud to continue to work with the administration in ensuring affordability for American patients, while preserving America’s position at the forefront of medical innovation.”
Other drugs listed on Trump’s DTC platform are fertility treatments, inhalers, and insulin. Additional drugs from other companies that have signed MFN pricing deals will be made available through TrumpRx.gov in the coming months, the White House said.
This will include drugmakers such as Johnson & Johnson, AbbVie, and MSD, amongst others. In total, 16 major pharmaceutical companies have signed MFN deals with the Trump administration. MFN is a policy framework that ties US drug prices to the lowest prices in other developed countries.
Amid the launch of TrumpRx, several companies have warned of financial headwinds in 2026 due to pricing changes in the US. In its earnings report earlier this week, Pfizer said its sales guidance for the upcoming year would be hit by an “unfavourable impact” because of its deal with Trump. Both Eli Lilly and Novo Nordisk also anticipate price erosions for their weight loss products in 2026.
